| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10966332 | Vaccine | 2013 | 7 Pages |
Abstract
One dose of PCV13 is more cost-effective for immunocompromised individuals than previous vaccination recommendations and may be more economically reasonable than current recommendations, depending on life expectancy and vaccine effectiveness in the immunocompromised.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Kenneth J. Smith, Mary Patricia Nowalk, Mahlon Raymund, Richard K. Zimmerman,